Table 5.
Plasma glucose rate of appearance (R a, μmol/(min·kg)) and glucose oxidation (Ox, μmol/(min·kg)) reported in the canine literature (data means are presented).
| Reference | Experimental groups (conditions) | BW, kg | R a | Ox |
|---|---|---|---|---|
| [14] | 2-3H [basal∗; methylprednisolone] | 21.1 | 22; 40.1 | — |
| 3-3H [basal; methylprednisolone] | 21.1 | 14.4; 18.4 | — | |
| U-14C [basal; methylprednisolone] | 21.1 | 14.4; 19.3 | — | |
|
| ||||
| [15] | Healthy; obese | 12.2; 17.5 | 15.6; 13.9 | — |
|
| ||||
| [13] | Clamped euglycemia [0; 7; 40; 120 mU/kg/h constant insulin infusion] | 22 | 19.1; 17.9; 54.7; 101.7 | — |
| Clamped hyperglycemia [0; 7; 40; 120 mU/kg/h constant insulin infusion] | 22 | 36; 46.1; 96.1; 167.8 | — | |
|
| ||||
| [16] | Healthy [saline; AICAR†; methypalmoxirate; AICAR and methypalmoxirate] | 20.1 | 13; 17.5; 14.5; 16 | — |
| Diabetic [saline; AICAR; methypalmoxirate; AICAR and methypalmoxirate] | 20.1 | 32.4; 31.6; 23.6; 21.9 | — | |
|
| ||||
| [17] | Saline infusion; pulsatile; constant octanoate infusion | — | 16.7; 18.3; 14.4 | — |
|
| ||||
| [18] | Baseline; 6 wk; 12 wk moderate-fat feeding | 27.5; —; 29 | 14.4; 18.3; 18.3 | — |
|
| ||||
| [19] | Saline; nicotinic acid | — | 15; 24 | 6; 14 |
|
| ||||
| [20] | Basal | 20.4 | 12.7 | — |
|
| ||||
| [21] | Basal [U-14C; 3-3H] | 15.2 | 8.7; 13.9 | — |
|
| ||||
| [22] | Basal | — | 24.3 | — |
|
| ||||
| [23] | Basal [saline; high FFA‡; low FFA infusion] | — | 15.3; 15.3; 15.3 | 5; 4.8; 8.9 |
| Epinephrine infusion [saline; high FFA; low FFA infusion] | — | 15; 15.8; 15.3 | 4.9; 5.2; 9.7 | |
| Propranolol and phentolamine infusion [saline; high FFA; low FFA infusion] | — | 15.2; 15.0; 15.2 | 5.1; 5.1; 9.8 | |
|
| ||||
| Overall mean and SE | 20.9 ± 0.6 | 26.8 ± 4.3 | 7.1 ± 0.9 | |
∗Basal refers to fasted rest.
†AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide.
‡FFA: free fatty acids.